Solid Biosciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLDB research report →
Companywww.solidbio.com
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy.
- CEO
- Alexander G. Cumbo
- IPO
- 2018
- Employees
- 100
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $492.39M
- P/E
- -3.62
- P/S
- 0.00
- P/B
- 1.85
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -74.45%
- ROIC
- -49.76%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-174,325,000 · -39.80%
- EPS
- $-1.99 · 34.97%
- Op Income
- $-179,206,000
- FCF YoY
- -56.40%
Performance & Tape
- 52W High
- $8.87
- 52W Low
- $2.68
- 50D MA
- $7.53
- 200D MA
- $6.18
- Beta
- 2.47
- Avg Volume
- 1.30M
Get TickerSpark's AI analysis on SLDB
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 29, 26 | Howton David T | other | 79,341 |
| Jan 29, 26 | Brooks Gabriel | other | 58,847 |
| Jan 29, 26 | Cumbo Alexander | other | 169,401 |
| Jan 29, 26 | Herzich Paul | other | 54,925 |
| Jan 29, 26 | Tan Kevin | other | 56,647 |
| Jan 29, 26 | Hanrahan Jessie | other | 54,925 |
| Apr 2, 26 | SMITH IAN F | other | 3,441 |
| Apr 2, 26 | SMITH IAN F | other | 3,441 |
| Mar 9, 26 | PERCEPTIVE ADVISORS LLC | other | 8,912,655 |
| Feb 13, 26 | Cumbo Alexander | other | 30,031 |
Our SLDB Coverage
We haven't published any research on SLDB yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLDB Report →